National Cancer Institute (NCI): Breast Neoplasms trials

The registry lists 253 Breast Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 20 are open to participants now and 80 have results posted.

Early Phase 1 2Phase 1 96Phase 2 109Phase 3 19No phase 47(a study in two phases counts in both)

Studies

Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic RiskCompletedNCT00043472
• Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian CancerCompletedNCT00040222
• Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast CancerTerminatedNCT00039455Phase 1
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Decitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00030615Phase 1
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00030537Phase 2
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsCompletedNCT00028535Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• High-Risk Breast Duct EpitheliumCompletedNCT00028340
• Study of Etoposide in Breast Cancer PatientsCompletedNCT00026949
• PS-341 in Treating Women With Metastatic Breast CancerCompletedNCT00025584Phase 2
• Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast CancerCompletedNCT00024154Phase 2
• Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast CancerCompletedNCT00020410Phase 1
• Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00020332Phase 1/2
• Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00020267Phase 1
• Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast CancerCompletedNCT00020176Phase 2
• Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian CancerCompletedNCT00019916Phase 1/2
• Raloxifene in Preventing Breast Cancer in Premenopausal WomenCompletedNCT00019500Phase 2
• LMB-9 Immunotoxin in Treating Patients With Advanced Solid TumorsCompletedNCT00019435Phase 1
• Vaccine Therapy and Biological Therapy in Treating Patients With Advanced CancerCompletedNCT00019084Phase 2
• Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast CancerCompletedNCT00017394Phase 2
• Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast CancerCompletedNCT00016549Phase 2
• Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast CancerTerminatedNCT00016276Phase 3
• Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle StudyCompletedNCT00006425
• Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up StudyCompletedNCT00006421
• Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast CancerCompletedNCT00006228Phase 2
• Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast CancerCompletedNCT00005970Phase 3
• Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast CancerCompletedNCT00005817Phase 2
• Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced CancerTerminatedNCT00005655Phase 1
• Susceptibility to Breast CancerCompletedNCT00004565
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Gene Therapy Plus Chemotherapy in Treating Patients With Breast CancerCompletedNCT00004038Phase 1
• Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2CompletedNCT00003992Phase 2
• Irofulven in Treating Patients With Metastatic Breast CancerCompletedNCT00003796Phase 2
• Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or MetastaticCompletedNCT00003440Phase 3
• Methods in Education for Breast Cancer GeneticsCompletedNCT00001806Phase 3
• A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by RituximabCompletedNCT00001805Phase 2
• Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast CancerCompletedNCT00001507Phase 1
• A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer PatientsCompletedNCT00001504Phase 1
• A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast CancerCompletedNCT00001498Phase 2
• Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast CancerCompletedNCT00001496
• Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast CancerCompletedNCT00001493Phase 2
• Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive ChemotherapyCompletedNCT00001440Phase 1
• Positron Emission Tomography in Patients With Breast CancerCompletedNCT00001385
• A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer PatientsCompletedNCT00001384Phase 2
• A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast CancerCompletedNCT00001378Phase 1
• A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast CancerCompletedNCT00001338Phase 3
• Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and LymphomaCompletedNCT00001270Phase 1
• Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast CancerCompletedNCT00001269Phase 1
• Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized TrialCompletedNCT00001250Phase 2
• Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast CancerCompletedNCT00001239Phase 2
• A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast CancerCompletedNCT00001193Phase 2